STERIS plc

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Surgical Equipment & Consumables - Diversified Stocks Q4 Earnings: STERIS (NYSE:STE) Firing on All Cylinders

AI-generated analysis

🦠 STERIS (NYSE:STE) reported Q4 revenues of $1.50 billion, representing a 9.2% year-over-year increase that beat analyst expectations by 1.1%.

πŸ“‰ Despite the revenue beat, STERIS shares have dropped 14.8% since reporting and currently trade at $225.79.

πŸ₯ The surgical equipment industry benefits from consistent demand driven by aging populations and recurring consumable revenue.

⚠️ Industry headwinds include high R&D costs, regulatory compliance expenses, intense competition, and pressure to reduce healthcare costs.

πŸ’‘ Future tailwinds for the sector involve the integration of AI and robotics into surgical procedures.

πŸ“Š As a group, the five tracked surgical equipment stocks missed analysts' consensus revenue estimates by 1.5% in Q4.

πŸ“‰ On average, the shares of these five companies have declined by 8% since the latest earnings results.

πŸ”¬ Solventum (NYSE:SOLV) reported $2.00 billion in revenue, a 3.7% year-over-year decrease that still beat analysts' expectations by 1.9%.

πŸ“‰ Solventum's stock is down 8.4% since reporting and trades at $70.48 despite beating organic revenue estimates.

⚠️ Solventum delivered the biggest analyst estimates beat but missed its EPS estimates significantly.

πŸ”¬ Becton Dickinson (NYSE:BDX) reported $4.49 billion in revenue, up 3.5% year-over-year but fell short of expectations by 12.8%.

πŸ“‰ BD's stock has plummeted 23.3% since results and trades at $161.04 due to missing full-year EPS guidance.

🦴 Zimmer Biomet (NYSE:ZBH) achieved the fastest revenue growth in the peer group with a 10.9% year-over-year increase to $2.24 billion.

πŸ“ˆ Zimmer Biomet's stock is the only one up, rising 6.8% since reporting and currently trading at $95.82.

πŸ”¬ Zimmer Biomet beat revenue estimates by 0.9% but slightly missed its full-year EPS guidance estimates.

βš•οΈ CONMED (NYSE:CNMD) reported $373.2 million in revenue, up 7.9% year-over-year, topping analysts' expectations by 1.7%.

πŸ“‰ CONMED faces challenges as it significantly missed full-year EPS guidance and failed to meet revenue expectations.

πŸ“ˆ The stock is up 1.1% since reporting and trades at $39.10 despite missing its broader annual guidance.

Bullish Signals
  • STERIS (NYSE:STE) reported Q4 revenues of $1.50 billion, representing a 9.2% year-on-year increase that exceeded analysts' expectations by 1.1%.
  • The company's growth is supported by tailwinds such as an aging population requiring more surgical interventions and the increasing integration of AI and robotics for innovation.
  • Solventum (NYSE:SOLV) delivered the biggest analyst estimates beat among its peers with organic revenue growing despite a broader industry slowdown.
  • Zimmer Biomet (NYSE:ZBH) achieved the fastest revenue growth among its tracked peers, posting revenues of $2.24 billion up 10.9% year-on-year and beating estimates by 0.9%.
  • Notably, Zimmer Biomet's stock is up 6.8% since reporting results, demonstrating strong market confidence in its orthopedic and robotic technologies.
  • CONMED (NYSE:CNMD) reported revenues of $373.2 million, a 7.9% year-on-year increase that topped analysts' expectations by 1.7%.
  • The broader surgical equipment industry benefits from consistent demand driven by recurring consumable revenue and long-term contracts with healthcare providers.
Risk Factors
  • The group of five tracked surgical equipment & consumables stocks reported a slower Q4, with combined revenues missing analysts' consensus estimates by 1.5%.
  • On average, share prices for these companies have declined 8% since the latest earnings results, indicating investor dissatisfaction despite mixed top-line results.
  • STERIS (NYSE:STE) stock is down 14.8% since reporting, currently trading at $225.79, despite a revenue beat that was narrow.
  • Solventum (NYSE:SOLV) recorded a significant miss of analysts' EPS estimates and saw its stock drop 8.4% to trade at $70.48.
  • Becton Dickinson (NYSE:BDX) significantly missed both analysts' full-year EPS guidance and revenue estimates by 12.8%, causing its stock to fall 23.3% to $161.04.
  • The industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and widespread efforts to reduce healthcare costs which may constrain profitability.
  • High costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, continue to threaten the sector's margins.
Full Analysis
The article reviews Q4 earnings results for five major surgical equipment and consumables diversified stocks, noting that the industry group collectively reported slower growth with revenues missing analysts' consensus estimates by 1.5%. Following these results, average share prices for the sector have declined approximately 8%. The text outlines industry dynamics where consistent demand driven by aging populations and recurring revenue is offset by high R&D costs, regulatory pressures, and pricing constraints from cost-conscious customers. STERIS reported Q4 revenues of $1.50 billion, a 9.2% year-over-year increase that exceeded analysts' expectations by 1.1%. Despite this top-line beat, the quarter was characterized as mixed due to the narrow revenue beat, leading the stock to fall 14.8% since reporting and trade at $225.79. Solventum reported revenues of $2.00 billion, down 3.7%, which still outperformed analyst expectations by 1.9%; however, it missed EPS estimates significantly, causing its stock to decline 8.4% to a price of $70.48 despite having the largest revenue beat among its peers. Becton Dickinson posted revenues of $4.49 billion, up 3.5%, but fell short of analyst expectations by 12.8% after missing both full-year EPS guidance and revenue estimates. This weak performance relative to analysts resulted in its stock dropping 23.3% to trade at $161.04. In contrast, Zimmer Biomet achieved the fastest revenue growth among its peers with revenues of $2.24 billion, up 10.9%, beating analyst expectations by 0.9%. While it also narrowly missed full-year EPS guidance, the stock remains resilient, trading up 6.8% at $95.82. CONMED reported revenues of $373.2 million, up 7.9%, topping revenue estimates by 1.7%, but significantly missed full-year earnings and revenue guidance; consequently, its stock only rose 1.1% to trade at $39.10. The article concludes with an unrelated narrative shift from late 2025 through early 2026 regarding market sentiment toward artificial intelligence and geopolitical risk. It describes how initial fears about AI eroding pricing power led investors to rotate into safer havens, only for the market focus to abruptly shift in spring 2026 from technological disruption to geopolitical tensions, specifically noting the US conflict with Iran as a dominant driver of market psychology by late 2025.